Among 32 patients with adenocarcinoma, 11 patients had activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), while 10 patiens were wild-type and 11 patients had unknown status. Here, EGFR is linked to adenocarcinoma.